Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Jul;5(4):170-8.
doi: 10.1155/1994/856850.

Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei

L E Bryan  1 , S Wong, D E Woods, D A Dance, W Chaowagul
Affiliations

Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei

L E Bryan et al. Can J Infect Dis. 1994 Jul.

Abstract
in English, French

Polyclonal and monoclonal antisera raised to tetanus toxoid-conjugated polysaccharide of lipopolysaccharide (lps) and purified lps of Pseudomonas pseudomallei that reacted with a collection of 41 strains of this bacterium from 23 patients are described. The common antigen recognized by these sera was within the polysaccharide component of the lps of the cells. The sera were specific for P pseudomallei in that none of 37 strains of other bacteria, including 20 Gram-negative and three Gram-positive species, were recognized, although cross-reaction occurred using the anticonjugate serum with some strains of Pseudomonas cepacia serotype A, a closely related bacterium. Passive protection studies using a diabetic rat model of P pseudomallei infection showed that partially purified rabbit polyclonal and mouse monoclonal antisera were protective when the median lethal dose was raised by four to five orders of magnitude. The wide distribution of the polysaccharide antigen among isolates of P pseudomallei used in this study and the protective role of antibody to the conjugated polysaccharide antigen suggest potential as a vaccine.

Les antiséra polyclonaux et monoclonaux élaborés contre le polysaccharide tétanique toxoïdo-conjugué du lipopolysaccharide (lps) et du lps purifié de Pseudomonas pseudomallei, qui ont réagi avec une série de 41 souches de cette bactérie provenant de 23 patients, sont décrits ici. L’antigène commun reconnu par ces sera se trouvait dans la composante polysaccharide du lps des cellules. Les seras étaient spécifiques au P pseudomallei en ce sens qu’aucune des 37 souches des autres bactéries, y compris 20 espèces gram-négatives et 3 espèces gram-positives n’a été reconnue, bien qu’une réaction croisée se soit produite lors de l’emploi de sérum anticonjugué avec des souches de Pseudomonas cepacia de sérotype A, une bactérie très apparentée. Des études de protection passive à l’aide d’un modèle d’infection à P pseudomallei chez le rat diabétique ont révélé que les antiséra partiellement purifiés polyclonaux de lapins et monoclonaux de souris conféraient une protection lorsque la dose létale médiane était multipliée par 4 ou 5. La grande distribution de l’antigène du polysaccharide parmi les isolats de P pseudomallei utilisés dans cette étude et le rôle protecteur de l’anticorps à l’endroit de l’antigène du polysaccharide donnent à penser qu’il pourrait jouer un rôle en vaccination.

Keywords: Lipopolysaccharide; Melioidosis; Pseudomonas pseudomallei; Vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lipopolysaccharide staining (28) patterns of 12 strains of proteinase K-digested whole cells of Pseudomonas pseudomallei. Strains in the lanes are: a,b: 365a; c: 365c; d: 392a; e,f: 392f; g, h: 316a; i: 316c; j: 305a; k: 305d; l: 415a; m: 415c; n: 443a; o: 443c
Figure 2
Figure 2
Elution profile from a Sephacryl S-500 column of carbohydrate reactive material from purified and hydrolyzed lipopolysaccharide conjugated to tetanus toxoid. A562 Reading in protein assay
Figure 3
Figure 3
Reaction of whole cell lipopolysaccharide of selected bacteria and antipolysaccharide serum (left) or monoclonal antibody (right) as shown by immunoblot reaction. Lanes are: a: Pseudomonas cepacia serotype B; b: Pseudomonas aeruginosa PAO503; c: P cepacia serotype C; d: P cepacia serotype A (K1 9-2); e: P cepacia serotype A (K1 9-2); f: P cepacia serotype D; g: Aeromonas hydrophilia; h: Yersinia enterocolitica; i: P pseudomallei 415b; j: P pseudomallei 305a; k: P pseudomallei 304b; l: P pseudomallei 199a
See this image and copyright information in PMC

References

    1. Dance DAB. Melioidosis: the tip of the iceberg. Clin Microbiol Rev. 1991;4:52–60. - PMC - PubMed
    1. Laeelarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis. 1989;11:413–25. - PubMed
    1. Woods ML, Currie BJ, Howard DM, et al. Neurological medioidosis – seven cases from the Northern Territory of Australia. Clin Infect Dis. 1992;15:163–9. - PubMed
    1. Dance DAB, Wuthiekanum V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother. 1989;24:295–309. - PubMed
    1. McKevitt AI, Retzer MD, Woods DE. Development and use of a serotyping scheme for Pseudomonas cepacia. Serodiagn Immunother. 1987;1:177–84.

LinkOut - more resources